DocumentRX-9710
Issued
Read2 min

Isomorphic Labs Banks $5 Billion Series C in AI Drug Discovery Push

Isomorphic Labs raised $5 billion in a Series C led by Greenoaks and Sequoia, the largest biopharma venture round tracked since 2022, after a $2.1 billion Series B in May.

TAG K-4629 · 473 words on the filing

AI drugmaker Isomorphic restocks with $5B fundraise
AI drugmaker Isomorphic restocks with $5B fundraiseDonnie0102 / pixabay

Summary of findings

  • Isomorphic Labs raised $5 billion in a Series C led by Greenoaks and Sequoia Capital, announced Tuesday.
  • The round follows a $2.1 billion Series B announced in May; Alphabet re-upped with continued significant investment.
  • The Series C is the largest financing tracked since 2022 among biopharma venture deals.
  • Partners include Novartis, Johnson & Johnson and Eli Lilly; positive preclinical results reported in oncology and immunology.
  • No AI-designed medicine has yet reached approval despite industry-wide AI investments from BMS, Merck, Lilly and Novo Nordisk this year.

Isomorphic Labs has raised $5 billion in a Series C round, the largest venture financing tracked in biopharma since 2022 and the second multibillion-dollar infusion for the Alphabet spinout this year.

Greenoaks and Sequoia Capital led the round, announced Tuesday. Alphabet provided what the company called "continued significant investment." Andreessen Horowitz joined as a new backer alongside existing investors. The round follows a $2.1 billion Series B announced in May, meaning Isomorphic has pulled in more than $7 billion across two raises in roughly half a year. The two deals rank as the biggest venture infusions of the year among the 26 firms tracked by trade press monitoring the sector.

Where does the money go?

The London-based company said the capital will fund its transition from building AI models to bringing medicines into the clinic, and will let it "expand deeper into new biology." Isomorphic, founded in 2021, says its platform can "deliver exquisitely engineered molecules with optimal drug-like properties" and tackle some of drug discovery's hardest problems.

The company reported positive preclinical results, both for partners and on internal programs, in oncology and immunology — results it says are "setting the stage for clinical entry." No trial names, endpoints or filing dates accompanied the announcement.

Isomorphic's partnership roster includes Novartis, Johnson & Johnson and Eli Lilly. Takeaway: the money buys a bridge from computation to first-in-human studies, the point where most AI-drugdiscovery claims meet their test.

Why is the timing notable?

The raise lands amid a rough stretch for the AI sector broadly. The downfall of Nvidia CEO Jensen Huang and election results reflecting voter anger over data centers have triggered a reckoning in the industry and a wider selloff of technology stocks.

Isomorphic's investors appear unfazed. Across the industry, both large and small drugmakers are rushing into AI this year. Bristol Myers Squibb, Merck & Co., Eli Lilly and Novo Nordisk have all announced significant investments or partnerships in 2025. Takeaway: for backers with pharma conviction, AI-drug-discovery exposure now outweighs AI-sector sentiment.

What can the technology actually deliver?

Skepticism persists. No medicine designed by AI has won approval. Even proponents of AI in drug discovery caution that the technology is unlikely to be a quick fix for the risks and failure rates inherent in pharmaceutical development.

The optimist case has prominent voices. Anthropic CEO Dario Amodei recently predicted AI could cure most major diseases within a decade. Isomorphic's own positioning sits between those poles: strong claims about molecule engineering, preclinical signal in two therapeutic areas, and no clinical data yet.

The $5 billion war chest removes funding as a constraint. The next measurable milestone is a clinical trial entry, which would make Isomorphic one of the first AI-native discovery companies to cross that line with an internally designed molecule.

via BioPharma Dive (Source)

Share this article:

More from Grace Kim

Grace Kim

Show full bio

Market editor covering companies, deals and strategy in global pharmaceutical industry at PharmInsider.

11 articles

Linked filings

  1. E-6328
  2. E-9238
  3. V-8604
  4. E-6700
  5. V-5496

« Previous filingNext filing »